Accelerating Access to Life-Saving Cell Therapies
Meet the Cell Shuttle
A factory-in-a-box for industrial scale cell therapy manufacturing.
“Cellares’ revolutionary technology will be a game changer for the cell therapy industry!”
Carl June, MD
Professor in Immunotherapy
University of Pennsylvania
Cellares Advisory Board Member
It’s Time to Automate
The potential of cell therapy is proven, but its impact is limited by manufacturing bottlenecks. Currently, there is no scalable manufacturing solution for cell therapies and existing processes are disjointed, cost prohibitive, failure prone and unable to meet market demand.
Cell Therapy Manufacturing Market by 2030
Source: Roots Analysis
Clinical Trials Underway
Source: Alliance for Regenerative Medicine
Of the Required Manufacturing Capacity Exists Today
Source: Kineticos Life Sciences
Taking on the Challenge
Cellares revolutionary technology is robust, cost-effective and will enable the parallel production of thousands of cell therapy doses per month. We’re saving lives by delivering safe and affordable access to novel cell therapies for patients in need.
True walk-away, end-to-end automation from loading the starting material to unloading a cell therapy product ready for administration.
Modular hardware supports the vast majority of cell therapy applications, including CAR-T, TCR, NK and HSC based workflows. A purpose-built process design software puts the power to define manufacturing workflows at your fingertips.
The first manufacturing platform that scales from high-throughput preclinical work to commercial scale, empowering you to meet market demand for your drug.
Three-fold reduction in process failure rates through elimination of operator error and contamination during open transfer steps.
Up to 70% cost reduction compared to open and manual manufacturing processes.
Join our Team
We are always looking for creative and passionate people to join our interdisciplinary team.
April 15th, 2021 – South San Francisco – Today, Cellares Co-Founder and CEO, Fabian Gerlinghaus was recognized in the 2021 Power List, celebrating the most…
February 11th, 2021 – South San Francisco – Cellares Corporation, a biotechnology company focused on revolutionizing cell therapy manufacturing…
February 8th, 2021 – Products from Novartis and Gilead proved it was possible to win regulatory approval for chimeric antigen receptor T cell…
April 15th, 2021 - South San Francisco - Today, Cellares Co-Founder and CEO, Fabian Gerlinghaus was recognized in the 2021 Power List, celebrating the most...
February 11th, 2021 – South San Francisco – Cellares Corporation, a biotechnology company focused on revolutionizing cell therapy manufacturing...
February 8th, 2021 - Products from Novartis and Gilead proved it was possible to win regulatory approval for chimeric antigen receptor T cell...